Intercept Pharma (ICPT) Announces Phase 3 REGENERATE Study in NASH Met Primary Endpoint
Tweet Send to a Friend
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced positive results from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE